- EED226
-
- $48.00
-
2026-08-30
- CAS:2083627-02-3
- Purity: 98.98%
- Supply Ability: 10g
- EED226
-
-
2026-07-20
- CAS:2083627-02-3
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 1000kg
|
| Product Name: | EED226 | | Synonyms: | EED226;N-(furan-2-ylmethyl)-8-(4-(methylsulfonyl)phenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine;MAK683(EED226/Compound 43);CS-2549;EED226;EED 226;EED226;EED 226;MAK683;1,2,4-Triazolo[4,3-c]pyrimidin-5-amine, N-(2-furanylmethyl)-8-[4-(methylsulfonyl)phenyl]-;N-[(furan-2-yl)methyl]-8-(4-methanesulfonylphenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine | | CAS: | 2083627-02-3 | | MF: | C17H15N5O3S | | MW: | 369.4 | | EINECS: | | | Product Categories: | | | Mol File: | 2083627-02-3.mol |  |
| | EED226 Chemical Properties |
| density | 1.49±0.1 g/cm3(Predicted) | | storage temp. | -20° | | solubility | Soluble in DMSO (up to 25 mg/ml). | | form | solid | | pka | 1.19±0.30(Predicted) | | color | Off-white | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month. |
| | EED226 Usage And Synthesis |
| Description | EED-226 (2083627-02-3) is a potent (IC50= 23.4 nM) and selective allosteric inhibitor of the EED subunit of the methyltransferase polycomb repressive complex 2 (PRC2).It caused drastic proliferation inhibition in lymphoma cells with EZH2 mutations and caused shrinkage and slower tumor growth in mice using a subcutaneous xenograft model of Karpas422. | | Uses | EED 226 is a potent, selective and orally bioavailable EED inhibitor, inducing robust and sustained tumor regression in specific models. Effective PRC2 inhibitorin the treatment of PRC2-dependant cancers. | | in vivo | EED226 induces robust and sustained tumor regression in EZH2MUT pre-clinical DLBCL model. In CD-1 mice, dosing of EED226 for 14 days at 300 mg/kg bid is well tolerated with no apparent adverse effects. It has very low in vivo clearance, and approximately 100% oral bioavailability. EED226 has low volume of distribution (0.8 L/kg), reasonable terminal t1/2 (2.2 h), and moderate plasma protein binding (PPB)[2]. | | storage | Store at -20°C | | References | [1] YING HUANG*. Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy[J]. Journal of Medicinal Chemistry, 2017, 60 6: 2215-2226. DOI:10.1021/acs.jmedchem.6b01576
[2] WEI QI. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED[J]. Nature chemical biology, 2017, 13 4: 381-388. DOI:10.1038/nchembio.2304 |
| | EED226 Preparation Products And Raw materials |
|